Geoffrey McDonough - Swedish Orphan Insider

BIOVF -- USA Stock  

USD 27.70  4.15  17.62%

  CEO
Dr. Geoffrey McDonough, M.D. no longer serves as President and Chief Executive Officer of Swedish Orphan Biovitrum AB effective as of July 1, 2017. He has held the position since August 15, 2011. He is also Board member of Zafgen and PTC Therapeutics. He previously served for Genzyme Corporationrationration in the United States from 2002, where he has over the years held such roles as Senior Vice President and General Manager, Personalized Genetic Health Senior Vice President, Global Business Unit Leader, LSD Therapeutics, and most recently, President of Europe, Middle East, and Africa . Prior to joining Genzyme, he worked as a pediatrician in the United States, and was also President, and Cofounder of Catalyst Medical Solutions Inc. He graduated from Harvard Medical School with a Medical Doctor degree. He holds a Bachelor of Arts in Philosophy and a BS in Biology degrees from the University of North Carolina.
Age: 44  CEO Since 2011  Ph.D    
46 86 97 20 00  http://www.sobi.com

Management Efficiency

The company has return on total asset (ROA) of 11.67 % which means that it generated profit of $11.67 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 22.83 % meaning that it generated $22.83 on every $100 dollars invested by stockholders.
The company has accumulated 675.6 K in total debt. Swedish Orphan Biovitrum AB has Current Ratio of 1.85 which is within standard range for the sector.

Similar Executives

Entity Summary

Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. Swedish Orphan is traded on OTC Market in USA.Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Tomtebodav?gen 23A and employs 816 people.

Swedish Orphan Biovi Leadership Team

Hans Wigzell, Independent Director
Lennart Johansson, Director
Annette Clancy, Independent Director
Trista Morrison, Vice President - Communications for North America
Kirsti Gjellan, Senior Vice President Manufacturing Operations
Jorgen Winroth, Head of Investor Relations and VP
Milan Zdravkovic, Senior Vice President Head of Research & Development
Hans Schikan, Independent Director
Dennis Pedersen, Senior Vice President Human Resources
Helena Saxon, Director
Anders Edvell, Head of Marketing and Sales
Geoffrey McDonough, CEO
Lars Dreioee, Senior Vice President Chief Quality & Compliance Officer
Alan Raffensperger, COO and Sr. VP
Fredrik Berg, Head of Legal and Intellectual Property, Risk- Safety and Environment Management and General Counsel
BoGunnar Rosenbrand, Director, Employee Representative
Adine Axen, Independent Director
Birgitte Volck, Senior Vice President Chief Medical Officer
MatsOlof Wallin, CFO, Senior Vice President
Stefan Fraenkel, Vice President Head of Corporate Development
Hakan Bjorklund, Independent Chairman of the Board
Cecilia Forberg, Vice President Head of Project and Portfolio Management
Stephen James, Vice President Head of Drug Design and Development
Bo Hansen, Chairman of the Board
Armin Reininger, Senior Vice President Head of Global Medical and Scientific Affairs
Catarina Larsson, Director, Employee Representative
Henrik Stenqvist, CFO
David Allsop, Director
Elisabeth Svanberg, Director
Wills HughesWilson, Senior Vice President and Chief Patient Access Officer
Guido Oelkers, President CEO
Jeffrey Jonas, Independent Director
Matthew Gantz, Director
Theresa Heggie, Independent Director

Stock Performance Indicators

Current Sentiment - BIOVF

Swedish Orphan Biovi Investor Sentiment
Macroaxis portfolio users are unresponsive in their opinion about investing in Swedish Orphan Biovitrum AB. What is your outlook on investing in Swedish Orphan Biovitrum AB? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Swedish Orphan and Apple. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Pattern Recognition module to use different pattern recognition models to time the market across multiple global exchanges.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">